Oil Prices Drop as Middle East Supply Recovery Eases Market Concerns 
TrumpRx Expands Discount Drug Access With 600 Generic Medications 
Wall Street Ends Mixed as Micron Surges, Apple Drops After Price Hikes 
Bain Capital Nears Deal for Majority Stake in Volkswagen Marine Engine Unit Everllence 
Alphabet Replaces Verizon in Dow Jones Industrial Average 
Samsung, SK Hynix to Unveil Record AI and Semiconductor Investment Plans Worth Over $646 Billion 
Senate Sets December 8 Vote on Trump’s NASA Nominee Jared Isaacman 
SK Hynix Targets $29.4 Billion Nasdaq Listing to Expand AI Chip Business 
Bayer Wins Major U.S. Supreme Court Roundup Lawsuit, Shares Surge 
Hantavirus Cruise Ship Outbreak Triggers Global Health Alert 
Trump Requests $11 Billion More in Farm Aid as Rising Costs Pressure U.S. Farmers 
SpaceX’s Starship Completes 11th Test Flight, Paving Way for Moon and Mars Missions 
Is space worth the cost? Accounting experts say its value can’t be found in spreadsheets 
SpaceX Stock Rebounds After Sharp Selloff, But Valuation Concerns Persist 
Apple Supplier Stocks Slide as Samsung, SK Hynix Lead Selloff After Apple Price Hikes 
Fortescue Faces Class Action Over Sexual Harassment Claims at Australian Mining Sites 
NIH Infectious Disease Leadership Shake-Up Raises Concerns Amid Ebola, Hantavirus Outbreaks 
Fujirebio Holding is now doubling down on developing blood tests to detect Alzheimer’s against which blockbuster therapy is expected soon.
The tiny Tokyo-based diagnostics firm, a unit of H.U. Group Holdings, which has a market value of $1.2 billion, developed the first US-approved spinal fluid test for Alzheimer’s.
According to Goki Ishikawa, the CEO of Fujirebio, the firm is boosting its lineup of reagents used to detect Alzheimer’s biomarkers in blood tests. It aims to file these tests for approval in the US as early as 2023.
Ishikawa said that the lineups offered by industry leaders are still limited, so they are rushing to create a solid lineup of tests.
